Industry Roundup: No GRAS For PHOs, Pfizer Expands In China, MusclePharm Targets Over-40 Consumers
This article was originally published in The Tan Sheet
Executive Summary
Partially hydrogenated oils lose GRAS; Pfizer expands consumer product output in China; MusclePharm adding direct sales; U.K. requires registration, logo for online sales; and more news in brief.
You may also be interested in...
CFSAN Priorities: Industry & Consumer Groups Weigh In On NDIs And More
FDA should accept safety findings from outside expert panels when reviewing new dietary ingredient notifications, CHPA says in Aug. 25 comments on CFSAN priorities
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.